<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102387</url>
  </required_header>
  <id_info>
    <org_study_id>H 552 000 - 0920</org_study_id>
    <secondary_id>2009-016627-56</secondary_id>
    <nct_id>NCT01102387</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections</brief_title>
  <official_title>Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at the Trunk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the efficacy and safety of once daily topical
      application of the combinational cream LAS41003 compared to the corresponding mono-substances
      in the treatment of candida infections in intertriginous areas at the trunk.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy and mycological culture</measure>
    <time_frame>Day 14</time_frame>
    <description>Clinical assesment scores and mycological status of candida (mycological culture)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical examination, AEs</measure>
    <time_frame>14 Days</time_frame>
    <description>Physician assesmentes of sign and symptoms (erythema, papules, pustules and maceration)
Percentage of local skin reactions, AEs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Candidiasis</condition>
  <arm_group>
    <arm_group_label>LAS41003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS189962</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS189961</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41003</intervention_name>
    <description>Once daily, topically</description>
    <arm_group_label>LAS41003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS189962</intervention_name>
    <description>Once daily, topically</description>
    <arm_group_label>LAS189962</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS189961</intervention_name>
    <description>Once daily, topically</description>
    <arm_group_label>LAS189961</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of candida infections in one or more intertriginous areas (trunk), confirmed
             by positive mycological sample at baseline;

          -  female volunteers of childbearing potential must either be surgically sterile
             (hysterectomy or tubal ligation) or agree to use a reliable method of contraception
             with a failure rate of less than 1 % per year when used consistently and correctly
             such as implants, injectables, combined oral contraceptives, some intra uterine
             devices [IUDs], sexual abstinence or vasectomized partner;

          -  written informed consent

        Exclusion Criteria:

          -  receiving systemic therapy with cytotoxic or immunosuppressive drugs either
             concurrently or within 12 weeks before the baseline visit;

          -  patients who have been treated with oral anti-fungal agents within the 12 weeks prior
             to study entry or treated with topical anti-fungal agents on the intertrigines within
             the previous 2 weeks;

          -  evidence of drug or alcohol abuse;

          -  pregnancy or nursing;

          -  symptoms of a clinically significant illness that may influence the outcome of the
             study in the four weeks before and during the study;

          -  treatment with any other investigational drug in the four weeks preceding the study;

          -  known allergic reactions to components of the study preparations, hypersensitivity
             against cetylstearyl alcohol;

          -  treatment with systemic or locally acting medications which might counter or influence
             the study aim within two weeks before the beginning of the study (e.g.
             glucocorticosteroids);

          -  in the opinion of the investigator or physician performing the initial examination the
             subject should not participate in the study, e.g. due to probable non-compliance or
             inability to
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Willers, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Almirall Hermal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site #5</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site #4</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site #2</name>
      <address>
        <city>Berlin</city>
        <zip>10961</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site #6</name>
      <address>
        <city>DÃ¼lmen</city>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site #1</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site #3</name>
      <address>
        <city>Vechta</city>
        <zip>49377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp</url>
    <description>Almirall Corporate Website</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Candida infections in intertriginous areas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

